The Ultimate Guide to the Best Asthma Inhalers Available in the USA
Updated: Sep 16
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Jan 24 2026
The best asthma inhalers available in the USA are not necessarily one particular brand or device—the right choice depends on your age, asthma severity, symptom pattern, previous attacks, inhaler technique, other medical conditions, and insurance or access. Asthma inhalers generally fall into two roles: medicines that provide rapid symptom relief and medicines that control the airway inflammation responsible for asthma. The U.S. Food and Drug Administration (FDA) has approved multiple options, including inhaled corticosteroids (ICS), bronchodilators, combination controller inhalers, and an ICS-SABA rescue inhaler for adults. Current international asthma guidance increasingly emphasizes corticosteroid-containing treatment because treating airway inflammation reduces the risk of serious attacks. This guide compares the major inhaler categories available in the United States, explains where familiar products fit, and highlights the questions that matter when choosing treatment. There is no universally “best” inhaler—the goal is to find an effective, safe treatment that matches the individual patient and can be used correctly.
What Types of Asthma Inhalers Are Available in the USA?
Asthma inhalers can be divided into relievers, controllers, and combination treatments. The important difference is not simply the brand name but what medicines the inhaler contains and what role those medicines play in asthma management.
The FDA describes two broad categories: quick-relief medicines that address symptoms when they occur and long-term control medicines intended to reduce symptoms and flare-ups over time.
Reliever inhalers
Traditional rescue inhalers contain a short-acting beta2-agonist (SABA), most commonly albuterol. These medicines quickly relax the muscles surrounding narrowed airways.
Examples of albuterol inhalers have included Ventolin HFA, ProAir HFA, and Proventil HFA, although specific branded products and generic availability can change over time. The FDA also recognizes levalbuterol as another short-acting bronchodilator option.
The limitation is important: albuterol opens narrowed airways but does not treat the underlying airway inflammation responsible for asthma. Current GINA recommendations therefore emphasize incorporating inhaled corticosteroid treatment rather than managing asthma with a SABA alone.
Controller inhalers
Controller treatment is intended to prevent symptoms and asthma attacks rather than simply respond when breathing becomes difficult.
Inhaled corticosteroids are central to asthma treatment because they suppress inflammation within the airways. Depending on the treatment step, an ICS may be used alone or combined with a long-acting bronchodilator.
Combination inhalers
Combination inhalers place two or sometimes three medicines into one device. Common combinations include:
ICS + LABA: an inhaled corticosteroid plus long-acting beta2-agonist
ICS + SABA: an inhaled corticosteroid plus short-acting beta2-agonist
ICS + LABA + LAMA: three medicines combining anti-inflammatory treatment with two types of bronchodilation
The appropriate combination depends on how well asthma is controlled and the patient's previous treatment.
Inhaler category | Examples of medicines | Main purpose | Important consideration |
SABA | Albuterol, levalbuterol | Rapid bronchodilation | Does not treat underlying airway inflammation |
ICS | Budesonide, fluticasone, beclomethasone, mometasone | Reduces airway inflammation | Usually taken according to a controller regimen |
ICS + LABA | Budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol | Controls inflammation while providing longer bronchodilation | Specific products have different approved uses and dosing |
ICS + SABA | Budesonide/albuterol | Relieves symptoms while delivering anti-inflammatory medicine | Airsupra is FDA-approved for adults 18+ |
ICS + LABA + LAMA | Triple combination therapy | Adds another bronchodilator for selected uncontrolled asthma | Generally considered when asthma remains uncontrolled despite other treatment |
The “best” asthma inhaler is better understood as the inhaler that provides the appropriate level of anti-inflammatory and bronchodilator treatment for a particular patient—and that the patient can use correctly and consistently.
Which Rescue Inhalers Are Available for Asthma?
Rescue treatment is used when symptoms occur, but the available options no longer consist only of traditional albuterol inhalers. An important development in the United States has been the availability of rescue treatment that combines rapid bronchodilation with an inhaled corticosteroid.
Albuterol inhalers
Albuterol has long been a familiar rescue medicine. It works quickly by relaxing smooth muscle surrounding the airways, helping relieve symptoms such as wheezing and breathlessness.
The FDA asthma treatment overview identifies albuterol as an example of quick-relief treatment. However, it also explains that asthma treatment needs to be selected with a healthcare professional because not every medicine is appropriate for every patient.
Current international guidance has shifted away from treating asthma exclusively with SABA rescue medication. GINA emphasizes that asthma involves airway inflammation and recommends ICS-containing treatment.
Airsupra: albuterol plus budesonide
Airsupra represents a different rescue approach. It combines albuterol, which rapidly opens the airways, with budesonide, an inhaled corticosteroid that treats inflammation.
The FDA approved Airsupra for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
According to current FDA prescribing information, each actuation delivers 90 mcg of albuterol and 80 mcg of budesonide. The labeled dose is two inhalations as needed, with no more than six doses—12 inhalations—in 24 hours.
In the MANDALA trial supporting approval, Airsupra reduced the risk of a severe asthma exacerbation by 28% compared with albuterol in the evaluated adult population with moderate-to-severe asthma.
That result applies to the studied population and should not be interpreted as meaning that Airsupra is automatically the appropriate rescue inhaler for every adult.
Which Controller and Combination Asthma Inhalers Are Commonly Used?
Controller inhalers are intended to reduce underlying airway inflammation and prevent future symptoms and attacks. Depending on the severity and pattern of asthma, treatment may involve an inhaled corticosteroid alone or a combination inhaler.
Inhaled corticosteroid inhalers
ICS medicines used in asthma include drugs such as:
Budesonide
Fluticasone
Beclomethasone
Mometasone
Products and formulations differ in approved ages, dosing schedules, devices, and strengths. They should not be assumed to be dose-for-dose interchangeable.
Inhaled corticosteroids are important because they address inflammation rather than simply opening narrowed airways. GINA's 2026 World Asthma Day guidance emphasizes access to ICS-containing treatment for people with asthma because these medicines reduce asthma attacks and preventable deaths.
ICS-LABA combination inhalers
People who require additional asthma control may be prescribed an inhaler combining an ICS with a LABA.
U.S. examples include formulations sold under brands such as Symbicort, Breyna, Advair, Wixela Inhub, Dulera, and Breo Ellipta, subject to their respective FDA-approved indications, age ranges, and current market availability.
These products should not be treated as interchangeable simply because they belong to the same broad category. They contain different drugs, use different devices, and may have different treatment roles.
Why budesonide-formoterol is different
Budesonide-formoterol combinations receive particular attention in modern asthma guidelines because formoterol has a rapid onset of bronchodilation.
GINA's 2026 strategy identifies ICS-formoterol as the ICS-LABA combination that can be used as an anti-inflammatory reliever. GINA Track 1, using ICS-formoterol as the reliever, remains its preferred treatment approach for adults and adolescents when available.
GINA reports that this strategy substantially reduces severe exacerbations, systemic corticosteroid exposure, and urgent healthcare requirements compared with SABA-based regimens.
However, FDA labeling and international guideline recommendations are not identical concepts. The exact U.S. prescribing instructions for a particular product should be followed.
How Do Popular Asthma Inhalers Compare?
The most useful comparison is not a ranking from “best” to “worst.” Instead, asthma inhalers should be compared according to their active ingredients, treatment role, device, approved population, and whether they address airway inflammation.
Example | Medicine type | General role in asthma | Key point |
Albuterol inhalers | SABA | Rapid symptom relief | Opens airways but does not itself treat airway inflammation |
Airsupra | Albuterol + budesonide | Anti-inflammatory rescue treatment | FDA-approved for as-needed treatment and exacerbation-risk reduction in adults 18+ |
Pulmicort | Budesonide ICS | Controller | Treats airway inflammation |
QVAR RediHaler | Beclomethasone ICS | Controller | ICS-only maintenance option |
Arnuity Ellipta | Fluticasone furoate ICS | Controller | Maintenance ICS delivered by a dry-powder device |
Symbicort / Breyna | Budesonide + formoterol | ICS-LABA combination | Provides anti-inflammatory treatment plus bronchodilation |
Advair / Wixela Inhub | Fluticasone + salmeterol | ICS-LABA combination | Maintenance treatment; not an acute rescue medicine |
Dulera | Mometasone + formoterol | ICS-LABA combination | Maintenance combination treatment |
Breo Ellipta | Fluticasone furoate + vilanterol | ICS-LABA combination | Once-daily maintenance option for appropriate patients |
Trelegy Ellipta | Fluticasone furoate + umeclidinium + vilanterol | ICS-LABA-LAMA | Triple maintenance therapy for selected adults |
Brand availability, generic alternatives, indications, and insurance coverage can change. The table is designed to explain treatment categories rather than provide a personal prescription or brand ranking.
How Do Doctors Choose the Right Asthma Inhaler?
There is no single best asthma inhaler because treatment needs to match both the disease and the person using the device. The decision begins with determining how well asthma is controlled and the person's risk of future exacerbations.
Previous asthma attacks matter
A person who has experienced serious exacerbations may require a different strategy from someone with infrequent symptoms and no recent attacks.
Preventing future attacks is a major goal even when everyday symptoms appear relatively mild. This is one reason modern guidelines place so much emphasis on anti-inflammatory treatment.
The inhaler device matters
Metered-dose inhalers and dry-powder inhalers require different techniques.
For example, a pressurized metered-dose inhaler generally requires coordination between actuation and inhalation unless used with an appropriate spacer. Dry-powder devices usually depend more heavily on the patient's ability to generate sufficient inspiratory flow.
GINA's 2026 guidance stresses correct inhaler technique and provides specific recommendations for pressurized metered-dose inhalers and spacers.
An excellent medicine delivered with poor technique may provide inadequate treatment.
Age and approved indication matter
Asthma medications are not automatically approved for every age group. Airsupra, for example, is currently FDA-approved for asthma in adults aged 18 years and older.
Other inhalers have their own age restrictions and FDA-approved indications. Children therefore need age-appropriate treatment rather than simply a smaller version of an adult regimen.
Cost and insurance can affect the practical choice
The inhaler prescribed on paper also needs to be accessible. Insurance formularies, deductibles, generic availability, pharmacy coverage, and manufacturer changes can influence out-of-pocket costs in the United States.
If cost prevents regular use, discuss alternatives with the prescriber or pharmacist rather than rationing controller medication. A clinically suitable alternative formulation or covered product may sometimes be available.
What Does Current Guidance Say About the Best Asthma Treatment Approach?
Current evidence increasingly supports asthma treatment that addresses airway inflammation whenever symptoms require treatment. The major shift is away from thinking of asthma solely as episodes of narrowed airways that need a bronchodilator.
GINA's 2026 guidance states that Track 1 using ICS-formoterol as an anti-inflammatory reliever remains its preferred approach for adults and adolescents when available. It cites lower risks of severe exacerbations and less systemic corticosteroid exposure compared with SABA-based regimens.
The 2026 GINA asthma management guidance provides the current international evidence-based framework for choosing treatment according to age, asthma control, exacerbation risk, and treatment step.
The U.S. treatment landscape also now includes an FDA-approved ICS-SABA rescue inhaler. Airsupra combines albuterol with budesonide for adults and is approved both for as-needed bronchoconstriction treatment or prevention and for reducing exacerbation risk.
The FDA approval information for Airsupra provides the indication, clinical-trial findings, and important safety information for this U.S.-approved option.
These developments do not make traditional inhalers obsolete. They mean clinicians now have additional ways to deliver anti-inflammatory treatment alongside symptom relief.
When Should Asthma Treatment Be Reviewed?
Asthma treatment should be reassessed when symptoms are becoming more frequent, you are waking at night because of asthma, normal activities are increasingly difficult, or you need your reliever more often than expected. These changes can indicate inadequate asthma control.
Do not simply increase doses or add another inhaler without medical guidance. A clinician may first need to check whether the diagnosis is correct, whether the inhaler is being used properly, whether prescribed treatment is being taken consistently, and whether factors such as smoking, allergens, occupational exposures, or other medical conditions are contributing.
Severe breathing difficulty, rapidly worsening symptoms, difficulty speaking because of breathlessness, confusion or drowsiness, or symptoms that do not respond to the prescribed rescue plan require urgent medical attention.
If you repeatedly need rescue medication, arrange a medical review even if the medicine temporarily works. FDA guidance notes that inadequately treated asthma can lead to life-threatening attacks requiring emergency care or hospitalization.
Conclusion
Choosing among the best asthma inhalers available in the USA is less about finding one winning brand and more about matching treatment to the individual. Albuterol inhalers provide rapid bronchodilation, Airsupra combines rescue bronchodilation with an inhaled corticosteroid for eligible adults, while ICS and ICS-LABA inhalers provide important long-term anti-inflammatory treatment. More intensive combination therapy is available when asthma remains uncontrolled.
Your prescriber can match the medicine, strength, device, and treatment strategy to your asthma and check that you can use the inhaler correctly. Do not switch inhalers or change prescribed doses on your own, and seek urgent care for severe or rapidly worsening breathing problems.
Frequently Asked Questions
1. What is the best inhaler for asthma in the USA?
There is no single best inhaler for everyone. The appropriate option depends on age, symptom frequency, previous attacks, current treatment, inhaler technique, and other health factors. Current guidelines emphasize ICS-containing treatment because controlling airway inflammation helps reduce the risk of serious exacerbations.
2. Is albuterol still used for asthma?
Yes. Albuterol remains a rapid-acting bronchodilator used to relieve asthma symptoms. However, albuterol alone does not treat underlying airway inflammation, and current international guidance emphasizes incorporating inhaled corticosteroid treatment rather than relying solely on SABA medication.
3. What is the newer rescue inhaler for asthma in the USA?
Airsupra is an FDA-approved rescue option combining albuterol with the corticosteroid budesonide. It is approved for as-needed bronchoconstriction treatment or prevention and to reduce exacerbation risk in people with asthma aged 18 and older. It is available only by prescription.
4. Is Symbicort a rescue or controller inhaler?
Symbicort contains budesonide and formoterol and is an ICS-LABA combination. Budesonide-formoterol has a special role in international anti-inflammatory reliever and maintenance-and-reliever strategies. However, patients in the United States should follow the FDA labeling and the specific regimen prescribed by their healthcare professional.
5. What is the difference between a steroid inhaler and a rescue inhaler?
An inhaled corticosteroid reduces airway inflammation and helps prevent asthma attacks. Traditional rescue inhalers such as albuterol primarily relax airway muscles for rapid symptom relief. Some newer strategies combine anti-inflammatory and rapid bronchodilator medicines within the same inhaler.
6. Should I change inhalers if my asthma is not controlled?
Your treatment may need adjustment, but do not switch inhalers yourself. Poor control can result from insufficient treatment, incorrect technique, inconsistent use, triggers, or another medical problem. A healthcare professional can assess the cause and decide whether changing the medicine, device, or treatment step is appropriate.
Comments